Switzerland's Kuros Biosciences swing to H1 profit as revenue jumps

Kuros Biosciences AG

13/08/2026 06:18

Overview
Switzerland bone graft maker's H1 2026 revenue rose 45% yr/yr
Company swung to net profit from loss in prior year period
Growth driven by commercial expansion, innovation, and operational investments

Outlook
Kuros confirms 2026 guidance of at least 35% sales growth and adj EBITDA margin around 14%
Company reiterates 2028 sales target of $300 mln to $330 mln, adj EBITDA margin at least 20%
Kuros says it remains on track toward mid-term growth and margin targets

Result Drivers
MARKET SHARE GAINS - Co said MagnetOs became the third-largest bone graft brand by U.S. revenue, gaining share against other products
COMMERCIAL EXPANSION - Co expanded MagnetOs into key growth segments, including extremities and trauma markets, and increased sales force
INNOVATION INVESTMENT - Co advanced its product pipeline and prepared new MagnetOs configurations for launch, while increasing R&D spending

Company press release: ID:nGNE30qV01

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Product Revenue
 
$92.35 mln
 
H1 Net Income
 
$4.41 mln
 
H1 Gross Profit
 
$79.97 mln
 
H1 Operating Income
 
$5.18 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Kuros Biosciences AG is CHF35.50, about 54.3% above its August 12 closing price of CHF23.00
The stock recently traded at 64 times the next 12-month earnings vs. a P/E of 65 three months ago

Reuters Recommended Reads
Aug 11 - Xtant Medical Q2 revenue falls on asset sales and lost license revenue
Aug 11 - Sanara MedTech Q2 revenue rises on soft-tissue product growth
Aug 12 - Germany's Medios H1 profit hit by pricing pressure; to buy 74% of Caelo to expand API

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)